Merck Exceeds Q1 Earnings Estimates with Strong Oncology Sales
Merck & Co. (NYSE:MRK) reported first-quarter results that exceeded analyst expectations, driven by strong performance in oncology and animal health. Shares rose over 4% in premarket trading. Revenue reached $16.29 billion, up 5% year-over-year, with KEYTRUDA sales rising 12% to $8.03 billion.
Tickers: $MRK
Topics: Acquisition Animal Health Earnings KEYTRUDA Merck Oncology Revenue Stock Price